Marinus Pharmaceuticals (NASDAQ: MRNS) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
This table compares Marinus Pharmaceuticals and Corcept Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Marinus Pharmaceuticals and Corcept Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Marinus Pharmaceuticals||N/A||N/A||-$28.64 million||($0.93)||-7.77|
|Corcept Therapeutics||$81.32 million||24.67||$8.14 million||$0.29||60.62|
Corcept Therapeutics has higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Marinus Pharmaceuticals has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Marinus Pharmaceuticals and Corcept Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Marinus Pharmaceuticals presently has a consensus price target of $11.00, suggesting a potential upside of 52.14%. Corcept Therapeutics has a consensus price target of $19.25, suggesting a potential upside of 9.50%. Given Marinus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than Corcept Therapeutics.
Insider and Institutional Ownership
19.0% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.3% of Corcept Therapeutics shares are owned by institutional investors. 6.4% of Marinus Pharmaceuticals shares are owned by insiders. Comparatively, 19.2% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Corcept Therapeutics beats Marinus Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation’s Abraxane) to treat patients with solid-tumor cancers.
Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.